Literature DB >> 29803740

Plakophilin3 loss leads to an increase in lipocalin2 expression, which is required for tumour formation.

Srikanta Basu1, Nazia Chaudhary1, Sanket Shah2, Carol Braggs3, Aakanksha Sawant3, Simone Vaz3, Rahul Thorat3, Sanjay Gupta2, Sorab N Dalal4.   

Abstract

An increase in tumour formation and metastasis are observed upon plakophilin3 (PKP3) loss. To identify pathways downstream of PKP3 loss that are required for increased tumour formation, a gene expression analysis was performed, which demonstrated that the expression of lipocalin2 (LCN2) was elevated upon PKP3 loss and this is consistent with expression data from human tumour samples suggesting that PKP3 loss correlates with an increase in LCN2 expression. PKP3 loss leads to an increase in invasion, tumour formation and metastasis and these phenotypes were dependent on the increase in LCN2 expression. The increased LCN2 expression was due to an increase in the activation of p38 MAPK in the HCT116 derived PKP3 knockdown clones as LCN2 expression decreased upon inhibition of p38 MAPK. The phosphorylated active form of p38 MAPK is translocated to the nucleus upon PKP3 loss and is dependent on complex formation between p38 MAPK and PKP3. WT PKP3 inhibits LCN2 reporter activity in PKP3 knockdown cells but a PKP3 mutant that fails to form a complex with p38 MAPK cannot suppress LCN2 promoter activity. Further, LCN2 expression is decreased upon loss of p38β, but not p38α, in the PKP3 knockdown cells. These results suggest that PKP3 loss leads to an increase in the nuclear translocation of p38 MAPK and p38β MAPK is required for the increase in LCN2 expression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Desmosome; Lipocalin2; Plakophilin3; p38 MAPK

Mesh:

Substances:

Year:  2018        PMID: 29803740     DOI: 10.1016/j.yexcr.2018.05.026

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

1.  Increased expression of plakophilin 3 is associated with poor prognosis in ovarian cancer.

Authors:  Hua Qian; Donglan Yuan; Jingjing Bao; Fuxing Liu; Wenyan Zhang; Xumei Yang; Gaohua Han; Junxing Huang; Haihui Sheng; Hong Yu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

2.  CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.

Authors:  Masami Miki; Takamasa Oono; Nao Fujimori; Takehiro Takaoka; Ken Kawabe; Yoshihiro Miyasaka; Takao Ohtsuka; Daisuke Saito; Masafumi Nakamura; Yasuyuki Ohkawa; Yoshinao Oda; Mikita Suyama; Tetsuhide Ito; Yoshihiro Ogawa
Journal:  Cancer Med       Date:  2019-05-25       Impact factor: 4.452

Review 3.  The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer.

Authors:  Laura García-Hernández; María Belén García-Ortega; Gloria Ruiz-Alcalá; Esmeralda Carrillo; Juan Antonio Marchal; María Ángel García
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 4.  p38β and Cancer: The Beginning of the Road.

Authors:  Olga Roche; Diego M Fernández-Aroca; Elena Arconada-Luque; Natalia García-Flores; Liliana F Mellor; María José Ruiz-Hidalgo; Ricardo Sánchez-Prieto
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

Review 5.  p38β - MAPK11 and its role in female cancers.

Authors:  Periklis Katopodis; Rachel Kerslake; Athanasios Zikopoulos; Nefeli Beri; Vladimir Anikin
Journal:  J Ovarian Res       Date:  2021-06-26       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.